Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Influenza

  Free Subscription


Articles published in Antiviral Res

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    August 2020
  1. MOHR PG, Williams J, Tashiro M, Streltsov VA, et al
    Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Antiviral Res. 2020 Aug 1:104895. doi: 10.1016/j.antiviral.2020.104895.
    PubMed     Abstract available


  2. BIALY D, Shelton H
    Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
    Antiviral Res. 2020 Aug 1:104886. doi: 10.1016/j.antiviral.2020.104886.
    PubMed     Abstract available


    July 2020
  3. CAI W, Wen H, Zhou Q, Wu L, et al
    14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activity.
    Antiviral Res. 2020 Jul 20:104885. doi: 10.1016/j.antiviral.2020.104885.
    PubMed     Abstract available


    June 2020
  4. MATYUSHENKO V, Kotomina T, Kudryavtsev I, Mezhenskaya D, et al
    Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell respo
    Antiviral Res. 2020 Jun 22:104864. doi: 10.1016/j.antiviral.2020.104864.
    PubMed     Abstract available


  5. TAKASHITA E, Abe T, Morita H, Nagata S, et al
    Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Antiviral Res. 2020 Jun 20:104828. doi: 10.1016/j.antiviral.2020.104828.
    PubMed     Abstract available


  6. JOCKUSCH S, Tao C, Li X, Anderson TK, et al
    A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
    Antiviral Res. 2020;180:104857.
    PubMed     Abstract available


  7. TILMANIS D, Koszalka P, Barr IG, Rossignol JF, et al
    Host-targeted Nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
    Antiviral Res. 2020 Jun 13:104851. doi: 10.1016/j.antiviral.2020.104851.
    PubMed     Abstract available


  8. SHANNON A, Le NT, Selisko B, Eydoux C, et al
    Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Antiviral Res. 2020;178:104793.
    PubMed     Abstract available


    May 2020
  9. TAI W, Zhang X, He Y, Jiang S, et al
    Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Antiviral Res. 2020 May 13:104820. doi: 10.1016/j.antiviral.2020.104820.
    PubMed     Abstract available


    April 2020
  10. MANTLO E, Bukreyeva N, Maruyama J, Paessler S, et al
    Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Antiviral Res. 2020;179:104811.
    PubMed     Abstract available


  11. ABED Y, Fage C, Checkmahomed L, Venable MC, et al
    Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Antiviral Res. 2020 Apr 25:104807. doi: 10.1016/j.antiviral.2020.104807.
    PubMed     Abstract available


  12. BRAY M, Rayner C, Noel F, Jans D, et al
    Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
    Antiviral Res. 2020 Apr 21:104805. doi: 10.1016/j.antiviral.2020.104805.
    PubMed    


  13. LAURE M, Hamza H, Koch-Heier J, Quernheim M, et al
    Antiviral efficacy against Influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model.
    Antiviral Res. 2020 Apr 15:104806. doi: 10.1016/j.antiviral.2020.104806.
    PubMed     Abstract available


  14. SALLARD E, Lescure FX, Yazdanpanah Y, Mentre F, et al
    Type 1 interferons as a potential treatment against COVID-19.
    Antiviral Res. 2020;178:104791.
    PubMed     Abstract available


  15. SUZUKI S, Shichinohe S, Itoh Y, Nakayama M, et al
    Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza A virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Antiviral Res. 2020 Apr 6:104790. doi: 10.1016/j.antiviral.2020.104790.
    PubMed     Abstract available


  16. TANG T, Bidon M, Jaimes JA, Whittaker GR, et al
    Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
    Antiviral Res. 2020 Apr 6:104792. doi: 10.1016/j.antiviral.2020.104792.
    PubMed     Abstract available


  17. CALY L, Druce JD, Catton MG, Jans DA, et al
    The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Apr 3:104787. doi: 10.1016/j.antiviral.2020.104787.
    PubMed     Abstract available


  18. CHOY KT, Yin-Lam Wong A, Kaewpreedee P, Sia SF, et al
    Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Antiviral Res. 2020 Apr 3:104786. doi: 10.1016/j.antiviral.2020.104786.
    PubMed     Abstract available


    March 2020
  19. SOLDEVILA N, Toledo D, Ortiz de Lejarazu R, Tamames S, et al
    Effect of antiviral treatment in older patients hospitalized with confirmed influenza.
    Antiviral Res. 2020 Mar 29:104785. doi: 10.1016/j.antiviral.2020.104785.
    PubMed     Abstract available


  20. JALILY PH, Duncan MC, Fedida D, Wang J, et al
    Put a cork in it: Plugging the M2 viral ion channel to sink influenza.
    Antiviral Res. 2020 Mar 27:104780. doi: 10.1016/j.antiviral.2020.104780.
    PubMed     Abstract available


  21. HUSSEIN AFA, Cheng H, Tundup S, Antanasijevic A, et al
    Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus.
    Antiviral Res. 2020 Mar 25:104782. doi: 10.1016/j.antiviral.2020.104782.
    PubMed     Abstract available


  22. SLOAN SE, Szretter KJ, Sundaresh B, Narayan KM, et al
    Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Antiviral Res. 2020 Mar 6:104763. doi: 10.1016/j.antiviral.2020.104763.
    PubMed     Abstract available


  23. TOURET F, de Lamballerie X
    Of chloroquine and COVID-19.
    Antiviral Res. 2020;177:104762.
    PubMed     Abstract available


  24. SIGRIST C, Bridge A, Le Mercier P
    A potential role for integrins in host cell entry by SARS-CoV-2.
    Antiviral Res. 2020 Mar 1:104759. doi: 10.1016/j.antiviral.2020.104759.
    PubMed    


    February 2020
  25. QIU H, Andersen H, Tarbet EB, Muhammad FS, et al
    Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus.
    Antiviral Res. 2020 Feb 27:104753. doi: 10.1016/j.antiviral.2020.104753.
    PubMed     Abstract available


  26. KUMARI R, Guo Z, Kumar A, Wiens M, et al
    Influenza virus NS1- C/EBPbeta gene regulatory complex inhibits RIG-I transcription.
    Antiviral Res. 2020 Feb 21:104747. doi: 10.1016/j.antiviral.2020.104747.
    PubMed     Abstract available


  27. MIFSUD EJ, Tilmanis D, Oh DY, Ming-Kay Tai C, et al
    Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
    Antiviral Res. 2020 Feb 20:104751. doi: 10.1016/j.antiviral.2020.104751.
    PubMed     Abstract available


    January 2020
  28. TAKASHITA E, Daniels RS, Fujisaki S, Gregory V, et al
    Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
    Antiviral Res. 2020 Jan 28:104718. doi: 10.1016/j.antiviral.2020.104718.
    PubMed     Abstract available


    November 2019
  29. PASCUA PNQ, Marathe BM, Bisen S, Webby RJ, et al
    Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
    Antiviral Res. 2019 Nov 29:104669. doi: 10.1016/j.antiviral.2019.104669.
    PubMed     Abstract available


    August 2019
  30. BAVAGNOLI L, Campanini G, Forte M, Ceccotti G, et al
    Identification of a novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human influenza virus and a corresponding viral escape mutation.
    Antiviral Res. 2019 Aug 27:104593. doi: 10.1016/j.antiviral.2019.104593.
    PubMed     Abstract available


  31. ARIKATA M, Itoh Y, Shichinohe S, Nakayama M, et al
    Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.
    Antiviral Res. 2019 Aug 14:104591. doi: 10.1016/j.antiviral.2019.104591.
    PubMed     Abstract available


    July 2019
  32. NG K, Raheem J, St Laurent CD, Marcet CT, et al
    Responses of human mast cells and epithelial cells following exposure to influenza A virus.
    Antiviral Res. 2019 Jul 23:104566. doi: 10.1016/j.antiviral.2019.104566.
    PubMed     Abstract available


  33. LI J, Yang Y, Wang M, Ren X, et al
    Rapid isolation of a potent human antibody against H7N9 influenza virus from an infected patient.
    Antiviral Res. 2019;170:104564.
    PubMed     Abstract available


  34. ABED Y, Fage C, Checkmahomed L, Begin G, et al
    The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors.
    Antiviral Res. 2019 Jul 16:104561. doi: 10.1016/j.antiviral.2019.104561.
    PubMed     Abstract available


  35. SEDEYN K, Saelens X
    New antibody-based prevention and treatment options for influenza.
    Antiviral Res. 2019 Jul 16:104562. doi: 10.1016/j.antiviral.2019.104562.
    PubMed     Abstract available


    June 2019
  36. MIFSUD EJ, Hayden FG, Hurt AC
    Antivirals targeting the polymerase complex of influenza viruses.
    Antiviral Res. 2019 Jun 24:104545. doi: 10.1016/j.antiviral.2019.104545.
    PubMed     Abstract available


  37. MCKIMM-BRESCHKIN JL, Barrett S, McKenzie-Kludas C, McAuley J, et al
    Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant.
    Antiviral Res. 2019;169:104542.
    PubMed     Abstract available


  38. ADAMS SE, Lee N, Lugovtsev VY, Kan A, et al
    Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.
    Antiviral Res. 2019;169:104539.
    PubMed     Abstract available


  39. ARTARINI A, Meyer M, Shin YJ, Huber K, et al
    Regulation of influenza a virus mRNA splicing by CLK1.
    Antiviral Res. 2019 Jun 6. pii: S0166-3542(18)30668.
    PubMed     Abstract available


    May 2019
  40. FARRUKEE R, Butler J, Reading PC, Hurt AC, et al
    Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Antiviral Res. 2019 May 24. pii: S0166-3542(18)30673.
    PubMed     Abstract available


  41. GEORGEL AF, Cayet D, Pizzorno A, Rosa-Calatrava M, et al
    Toll-like receptor 5 agonist flagellin reduces Influenza A Virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir.
    Antiviral Res. 2019 May 9. pii: S0166-3542(18)30570.
    PubMed     Abstract available


  42. KOTOMINA T, Isakova-Sivak I, Matyushenko V, Kim KH, et al
    Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
    Antiviral Res. 2019 May 7. pii: S0166-3542(19)30121.
    PubMed     Abstract available


    April 2019
  43. CHIBANGA VP, Dirr L, Guillon P, El-Deeb IM, et al
    New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase.
    Antiviral Res. 2019 Apr 2. pii: S0166-3542(18)30740.
    PubMed     Abstract available


  44. TARASOV SA, Zarubaev VV, Gorbunov EA, Sergeeva SA, et al
    Retraction notice to "Activity of ultra-low doses of antibodies to gamma-interferon against lethal influenza A(H1N1)2009 virus infection in mice" [Antiviral Research 93 (2012) 219-224].
    Antiviral Res. 2019;164:177.
    PubMed    


    March 2019
  45. NANNETTI G, Massari S, Mercorelli B, Bertagnin C, et al
    Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance.
    Antiviral Res. 2019 Mar 15. pii: S0166-3542(18)30659.
    PubMed     Abstract available


    February 2019
  46. KOSZALKA P, Tilmanis D, Roe M, Vijaykrishna D, et al
    Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
    Antiviral Res. 2019 Feb 13. pii: S0166-3542(18)30698.
    PubMed     Abstract available


  47. MOHL G, Liddle N, Nygaard J, Dorius A, et al
    Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5.
    Antiviral Res. 2019 Feb 8. pii: S0166-3542(18)30487.
    PubMed     Abstract available


  48. HONG JY, Chen TH, Chen YJ, Liu CC, et al
    Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.
    Antiviral Res. 2019;164:12-22.
    PubMed     Abstract available


  49. SCHOGLER A, Caliaro O, Brugger M, Oliveira Esteves BI, et al
    Modulation of the unfolded protein response pathway as an antiviral approach in airway epithelial cells.
    Antiviral Res. 2019;162:44-50.
    PubMed     Abstract available


    January 2019
  50. WATANABE A, Ishida T, Hirotsu N, Kawaguchi K, et al
    Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
    Antiviral Res. 2019;163:75-81.
    PubMed     Abstract available


  51. KIM MH, Kang JO, Kim JY, Jung HE, et al
    Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
    Antiviral Res. 2019 Jan 9. pii: S0166-3542(18)30589.
    PubMed     Abstract available


  52. ZHANG K, Li C, Luo YS, Wen L, et al
    Establishment of a lethal aged mouse model of human respiratory syncytial virus infection.
    Antiviral Res. 2019;161:125-133.
    PubMed     Abstract available


    December 2018
  53. GARG R, Latimer L, Gomis S, Gerdts V, et al
    Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Antiviral Res. 2018 Dec 11. pii: S0166-3542(18)30464.
    PubMed     Abstract available


    October 2018
  54. SONG L, Xiong D, Kang X, Jiao Y, et al
    The optimized fusion protein HA1-2-FliC big up tri, openD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Antiviral Res. 2018 Oct 30. pii: S0166-3542(18)30186.
    PubMed     Abstract available


  55. NOSHI T, Kitano M, Taniguchi K, Yamamoto A, et al
    In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
    Antiviral Res. 2018 Oct 11. pii: S0166-3542(18)30363.
    PubMed     Abstract available


  56. PICHON M, Picard C, Simon B, Gaymard A, et al
    Clinical management and viral genomic diversity analysis of a child's influenza A(H1N1)pdm09 infection in the context of a severe combined immunodeficiency.
    Antiviral Res. 2018;160:1-9.
    PubMed     Abstract available


    September 2018
  57. ABED Y, Tu V, Carbonneau J, Checkmahomed L, et al
    Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
    Antiviral Res. 2018 Sep 13. pii: S0166-3542(18)30313.
    PubMed     Abstract available


  58. KOLPE A, Schepens B, Ye L, Staeheli P, et al
    Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.
    Antiviral Res. 2018 Sep 1. pii: S0166-3542(18)30314.
    PubMed     Abstract available


    August 2018
  59. XIA C, Seo YJ, Studstill CJ, Vijayan M, et al
    Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice.
    Antiviral Res. 2018 Aug 17. pii: S0166-3542(18)30220.
    PubMed     Abstract available


  60. SOOD R, Kumar N, Bhatia S, Chanu KV, et al
    Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
    Antiviral Res. 2018 Aug 17. pii: S0166-3542(18)30167.
    PubMed     Abstract available


  61. BRODSKAIA AV, Timin AS, Gorshkov AN, Muslimov AR, et al
    Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers.
    Antiviral Res. 2018 Aug 6. pii: S0166-3542(17)30732.
    PubMed     Abstract available


    July 2018
  62. GARG R, Brownlie R, Latimer L, Gerdts V, et al
    A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Antiviral Res. 2018;158:78-87.
    PubMed     Abstract available


  63. SCHRADER T, Dudek SE, Schreiber A, Ehrhardt C, et al
    The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
    Antiviral Res. 2018 Jul 7. pii: S0166-3542(18)30364.
    PubMed     Abstract available


  64. LACKENBY A, Besselaar TG, Daniels RS, Fry A, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
    Antiviral Res. 2018;157:38-46.
    PubMed     Abstract available


    June 2018
  65. LA FRAZIA S, Piacentini S, Riccio A, Rossignol JF, et al
    The second-generation thiazolide haloxanide is a potent inhibitor of avian influenza virus replication.
    Antiviral Res. 2018 Jun 13. pii: S0166-3542(18)30079.
    PubMed     Abstract available


  66. KO EJ, Lee Y, Lee YT, Kim YJ, et al
    MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Antiviral Res. 2018 Jun 6. pii: S0166-3542(18)30007.
    PubMed     Abstract available


    May 2018
  67. CHAUDHURI S, Symons JA, Deval J
    Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.
    Antiviral Res. 2018 May 11. pii: S0166-3542(18)30180.
    PubMed     Abstract available


    March 2018
  68. MATOS AR, Resende PC, Miranda MD, Garcia CC, et al
    Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
    Antiviral Res. 2018 Mar 27. pii: S0166-3542(17)30768.
    PubMed     Abstract available


  69. MCKIMM-BRESCHKIN JL, Barrett S, Wong FYK, Pudjiatmoko, et al
    Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
    Antiviral Res. 2018;153:95-100.
    PubMed     Abstract available


  70. MALCOLM BA, Aerts CA, Dubois KJ, Geurts FJ, et al
    PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.
    Antiviral Res. 2018;153:70-77.
    PubMed     Abstract available


  71. MUSHARRAFIEH R, Ma C, Wang J
    Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.
    Antiviral Res. 2018 Mar 5. pii: S0166-3542(18)30065.
    PubMed     Abstract available


  72. GU H, Gao Y, Zhou S, Sun F, et al
    Bivalent vaccine platform based on ca influenza virus vaccine elicits protective immunity against human adenoviruses.
    Antiviral Res. 2018 Mar 1. pii: S0166-3542(17)30305.
    PubMed     Abstract available


    January 2018
  73. HUI DS, Lee N, Chan PK, Beigel JH, et al
    The role of adjuvant immunomodulatory agents for treatment of severe influenza.
    Antiviral Res. 2018;150:202-216.
    PubMed     Abstract available


    October 2017
  74. MARATHE BM, Mostafa HH, Vogel P, Pascua PNQ, et al
    A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
    Antiviral Res. 2017 Oct 31. pii: S0166-3542(17)30491.
    PubMed     Abstract available


  75. SARVESTANI ST, McAuley JL
    The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection.
    Antiviral Res. 2017 Oct 30. pii: S0166-3542(17)30611.
    PubMed     Abstract available


  76. KIM MC, Lee YN, Kim YJ, Choi HJ, et al
    Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
    Antiviral Res. 2017;148:43-52.
    PubMed     Abstract available


  77. GORDON NA, McGuire KL, Wallentine SK, Mohl GA, et al
    Divalent copper complexes as influenza A M2 inhibitors.
    Antiviral Res. 2017;147:100-106.
    PubMed     Abstract available


  78. TILMANIS D, van Baalen C, Oh DY, Rossignol JF, et al
    The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
    Antiviral Res. 2017 Oct 3. pii: S0166-3542(17)30546.
    PubMed     Abstract available


    September 2017
  79. WU Y, Yang D, Xu B, Liang W, et al
    Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.
    Antiviral Res. 2017 Sep 20. pii: S0166-3542(17)30180.
    PubMed     Abstract available


    August 2017
  80. GUBAREVA LV, Besselaar TG, Daniels RS, Fry A, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Antiviral Res. 2017 Aug 9. pii: S0166-3542(17)30267.
    PubMed     Abstract available


  81. PICHON M, Gaymard A, Josset L, Valette M, et al
    Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
    Antiviral Res. 2017 Aug 2. pii: S0166-3542(17)30431.
    PubMed     Abstract available


  82. HU Y, Zhang J, Musharrafieh RG, Ma C, et al
    Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.
    Antiviral Res. 2017;145:103-113.
    PubMed     Abstract available


  83. ZHANG S, Sun F, Ren T, Duan Y, et al
    Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice.
    Antiviral Res. 2017 Aug 1. pii: S0166-3542(16)30742.
    PubMed     Abstract available


    June 2017
  84. PAUL SS, Mok CK, Mak TM, Ng OW, et al
    A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.
    Antiviral Res. 2017 Jun 17. pii: S0166-3542(17)30042.
    PubMed     Abstract available


  85. LIU M, Lo EC, Wang G, Chow HF, et al
    Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening.
    Antiviral Res. 2017 Jun 16. pii: S0166-3542(16)30584.
    PubMed     Abstract available


  86. PETROVA NV, Emelyanova AG, Gorbunov EA, Edwards MR, et al
    Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.
    Antiviral Res. 2017;142:185-192.
    PubMed     Abstract available


    May 2017
  87. GIAROLA-SILVA S, Coelho-Dos-Reis JGA, Mourao MM, Campi-Azevedo AC, et al
    Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine.
    Antiviral Res. 2017;144:70-82.
    PubMed     Abstract available


  88. LEE N, Wong CK, Chan MCW, Yeung ESL, et al
    Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.
    Antiviral Res. 2017 May 20. pii: S0166-3542(17)30141.
    PubMed     Abstract available


  89. COURTIN N, Fotso AF, Fautrad P, Mas F, et al
    Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses.
    Antiviral Res. 2017;143:252-261.
    PubMed     Abstract available


    April 2017
  90. LIU JX, Zhang Y, Hu QP, Li JQ, et al
    Anti-inflammatory effects of rosmarinic acid-4-O-beta-D-glucoside in reducing acute lung injury in mice infected with influenza virus.
    Antiviral Res. 2017 Apr 28. pii: S0166-3542(16)30454.
    PubMed     Abstract available


  91. WANG M, Wang S, Wang W, Wang Y, et al
    Inhibition effects of novel polyketide compound PPQ-B against influenza A virus replication by interfering with the cellular EGFR pathway.
    Antiviral Res. 2017;143:74-84.
    PubMed     Abstract available


  92. WANG Y, Wu J, Xue C, Wu Z, et al
    A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Antiviral Res. 2017 Apr 10. pii: S0166-3542(16)30791.
    PubMed     Abstract available


  93. HAASBACH E, Muller C, Ehrhardt C, Schreiber A, et al
    The MEK-inhibitor CI-1040 displays a broad anti-influenza activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.
    Antiviral Res. 2017 Apr 1. pii: S0166-3542(17)30060.
    PubMed     Abstract available


  94. YANG JR, Cheng CY, Chen CY, Lin CH, et al
    A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Antiviral Res. 2017;140:62-75.
    PubMed     Abstract available


  95. ALBULESCU L, Bigay J, Biswas B, Weber-Boyvat M, et al
    Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.
    Antiviral Res. 2017;140:37-44.
    PubMed     Abstract available


    March 2017
  96. LEYVA-GRADO VH, Palese P
    Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
    Antiviral Res. 2017;142:12-15.
    PubMed     Abstract available


    February 2017
  97. PENDZIALEK J, Roose K, Smet A, Schepens B, et al
    Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
    Antiviral Res. 2017 Feb 28. pii: S0166-3542(16)30618.
    PubMed     Abstract available


  98. GAO L, Han J, Si J, Wang J, et al
    Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro.
    Antiviral Res. 2017 Feb 20. pii: S0166-3542(16)30540.
    PubMed     Abstract available


  99. COLEMAN BL, Hassan K, Green K, Gubbay JB, et al
    Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.
    Antiviral Res. 2017 Feb 5. pii: S0166-3542(16)30612.
    PubMed     Abstract available


  100. TAO W, Hurst B, Shakya AK, Uddin MJ, et al
    Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Antiviral Res. 2017 Feb 1. pii: S0166-3542(16)30409.
    PubMed     Abstract available


    January 2017
  101. HU Y, Musharrafieh R, Ma C, Zhang J, et al
    An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
    Antiviral Res. 2017 Jan 10. pii: S0166-3542(16)30522.
    PubMed     Abstract available


  102. TELCIAN AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, et al
    Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.
    Antiviral Res. 2017;137:93-101.
    PubMed     Abstract available


    December 2016
  103. KOBAYASHI M, Kodama M, Noshi T, Yoshida R, et al
    Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Antiviral Res. 2016 Dec 21. pii: S0166-3542(16)30327.
    PubMed     Abstract available


    November 2016
  104. YANG WT, Yang GL, Wang Q, Huang HB, et al
    Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Antiviral Res. 2016 Nov 28. pii: S0166-3542(16)30462.
    PubMed     Abstract available


  105. YUAN S, Chu H, Ye J, Singh K, et al
    Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface.
    Antiviral Res. 2016 Nov 10. pii: S0166-3542(16)30372.
    PubMed     Abstract available


  106. TU V, Abed Y, Barbeau X, Carbonneau J, et al
    The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Antiviral Res. 2016;137:6-13.
    PubMed     Abstract available


    October 2016
  107. SMEE DF, Barnard DL, Jones SM
    Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
    Antiviral Res. 2016 Oct 19. pii: S0166-3542(16)30404.
    PubMed     Abstract available


  108. WILSON JR, Guo Z, Reber A, Kamal RP, et al
    An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Antiviral Res. 2016 Oct 3. pii: S0166-3542(16)30341.
    PubMed     Abstract available


    February 2016
  109. SODERHOLM S, Anastasina M, Islam MM, Tynell J, et al
    Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
    Antiviral Res. 2016;126:69-80.
    PubMed     Abstract available


  110. LYTRAS T, Kossyvakis A, Mentis A
    NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
    Antiviral Res. 2016;126:18-20.
    PubMed     Abstract available


  111. YANG JR, Chen CY, Kuo CY, Cheng CY, et al
    A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Antiviral Res. 2016;126:8-17.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: